Denali Therapeutics and Biogen Announce Initiation of Phase

BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s diseasePhase...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Samantha Budd Haeberlein ,Walter Gilbert ,Charles Weissmann ,Heinz Schaller ,Angela Salerno Robin ,Ashleigh Koss ,Mike Hencke ,Laura Hansen ,Kenneth Murray ,Denali Therapeutics Inc ,Head Of Neurodegeneration Development At Biogen ,Linkedin ,Twitter ,Biogen Inc ,Global Safety Regulatory Sciences ,Nasdaq ,Exchange Commission ,Youtube ,Facebook ,Confirmed Worsening ,Movement Disorder Society Unified Parkinson ,Disease Rating Scale ,Chief Medical Officer ,Senior Vice President ,Neurodegeneration Development ,Denali Therapeutics ,South San ,Sir Kenneth Murray ,Nobel Prize ,Healthy Lives ,Private Securities Litigation Reform Act ,Global Safety ,Quarterly Reports ,Vice President ,Media Relations ,Investor Relations ,Nasdaq Dnli ,Arkinson 39s Disease ,